The comparative trials of fecal immunochemical testing vs. colonoscopy: What COLONPREV tells us and what to anticipate from the others.

Clin Gastroenterol Hepatol

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine; Center for Health Information and Communication, Health Services Research and Development, Richard L. Roudebush, VA Medical Center; The Regenstrief Institute, Inc; The Melvin and Bren Simon Co

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2025.08.026DOI Listing

Publication Analysis

Top Keywords

comparative trials
4
trials fecal
4
fecal immunochemical
4
immunochemical testing
4
testing colonoscopy
4
colonoscopy colonprev
4
colonprev tells
4
tells anticipate
4
comparative
1
fecal
1

Similar Publications

Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.

View Article and Find Full Text PDF

Background: Knee osteoarthritis (KOA) is a prevalent degenerative joint disorder that significantly impairs physical function and daily activities. While conventional treatments focus on symptom management, complementary therapies such as aromatherapy massage have gained attention for their potential benefits.

Objective: This study evaluates the effects of peppermint oil aromatherapy massage on functional impairments in KOA patients.

View Article and Find Full Text PDF

Background: Ecological momentary assessment (EMA) is increasingly being incorporated into intervention studies to acquire a more fine-grained and ecologically valid assessment of change. The added utility of including relatively burdensome EMA measures in a clinical trial hinges on several psychometric assumptions, including that these measure are (1) reliable, (2) related to but not redundant with conventional self-report measures (convergent and discriminant validity), (3) sensitive to intervention-related change, and (4) associated with a clinically relevant criterion of improvement (criterion validity) above conventional self-report measures (incremental validity).

Objective: This study aimed to evaluate the reliability, validity, and sensitivity to change of conventional self-report versus EMA measures of rumination improvement.

View Article and Find Full Text PDF

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Neurology

October 2025

Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.

Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).

View Article and Find Full Text PDF

Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.

View Article and Find Full Text PDF